Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
4105 | 1770 | 54.6 | 94% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
1350 | 7838 | KAPOSIS SARCOMA//HUMAN HERPESVIRUS 8//KSHV |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | PRIMARY EFFUSION LYMPHOMA | Author keyword | 183 | 75% | 7% | 131 |
2 | KSHV | Author keyword | 128 | 53% | 10% | 172 |
3 | TUMOR VIROL PROGRAM | Address | 52 | 58% | 3% | 60 |
4 | KAPOSIS SARCOMA ASSOCIATED HERPESVIRUS | Author keyword | 42 | 45% | 4% | 71 |
5 | VFLIP | Author keyword | 34 | 93% | 1% | 13 |
6 | HM BLIGH CANC S | Address | 29 | 55% | 2% | 36 |
7 | LANA | Author keyword | 27 | 70% | 1% | 23 |
8 | HHV 8 | Author keyword | 24 | 26% | 4% | 78 |
9 | ORF50 | Author keyword | 23 | 86% | 1% | 12 |
10 | BODY CAVITY BASED LYMPHOMA | Author keyword | 23 | 76% | 1% | 16 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | PRIMARY EFFUSION LYMPHOMA | 183 | 75% | 7% | 131 | Search PRIMARY+EFFUSION+LYMPHOMA | Search PRIMARY+EFFUSION+LYMPHOMA |
2 | KSHV | 128 | 53% | 10% | 172 | Search KSHV | Search KSHV |
3 | KAPOSIS SARCOMA ASSOCIATED HERPESVIRUS | 42 | 45% | 4% | 71 | Search KAPOSIS+SARCOMA+ASSOCIATED+HERPESVIRUS | Search KAPOSIS+SARCOMA+ASSOCIATED+HERPESVIRUS |
4 | VFLIP | 34 | 93% | 1% | 13 | Search VFLIP | Search VFLIP |
5 | LANA | 27 | 70% | 1% | 23 | Search LANA | Search LANA |
6 | HHV 8 | 24 | 26% | 4% | 78 | Search HHV+8 | Search HHV+8 |
7 | ORF50 | 23 | 86% | 1% | 12 | Search ORF50 | Search ORF50 |
8 | BODY CAVITY BASED LYMPHOMA | 23 | 76% | 1% | 16 | Search BODY+CAVITY+BASED+LYMPHOMA | Search BODY+CAVITY+BASED+LYMPHOMA |
9 | PEL | 20 | 48% | 2% | 31 | Search PEL | Search PEL |
10 | HUMAN HERPESVIRUS 8 | 17 | 21% | 4% | 75 | Search HUMAN+HERPESVIRUS+8 | Search HUMAN+HERPESVIRUS+8 |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | PRIMARY EFFUSION LYMPHOMA | 268 | 50% | 22% | 388 |
2 | MULTICENTRIC CASTLEMANS DISEASE | 196 | 52% | 15% | 266 |
3 | SARCOMA ASSOCIATED HERPESVIRUS | 173 | 25% | 33% | 590 |
4 | LYTIC SWITCH PROTEIN | 128 | 86% | 4% | 66 |
5 | EPISOME PERSISTENCE | 114 | 95% | 2% | 38 |
6 | HUMAN HERPESVIRUS 8 | 113 | 32% | 17% | 299 |
7 | KSHV | 88 | 51% | 7% | 122 |
8 | POLYADENYLATED NUCLEAR RNA | 85 | 86% | 2% | 43 |
9 | KAPOSIS SARCOMA | 81 | 13% | 32% | 559 |
10 | READING FRAME 50 | 79 | 88% | 2% | 37 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
The role of Kaposi sarcoma-associated herpesvirus in the pathogenesis of Kaposi sarcoma | 2015 | 2 | 143 | 60% |
KSHV Reactivation and Novel Implications of Protein Isomerization on Lytic Switch Control | 2015 | 2 | 168 | 49% |
Molecular Biology of KSHV Lytic Reactivation | 2015 | 1 | 251 | 86% |
Kaposi's sarcoma and its associated herpesvirus | 2010 | 172 | 181 | 60% |
Gammaherpesviruses and Lymphoproliferative Disorders | 2014 | 21 | 142 | 44% |
Novel functions of viral anti-apoptotic factors | 2015 | 1 | 44 | 52% |
AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV | 2013 | 20 | 177 | 67% |
KSHV infection and the pathogenesis of Kaposi's sarcoma | 2006 | 140 | 149 | 66% |
HIV-associated lymphomas and gamma-herpesviruses | 2009 | 101 | 143 | 43% |
Human Viral Oncogenesis: A Cancer Hallmarks Analysis | 2014 | 16 | 121 | 36% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | TUMOR VIROL PROGRAM | 52 | 58% | 3.4% | 60 |
2 | HM BLIGH CANC S | 29 | 55% | 2.0% | 36 |
3 | LOUISIANA CANC | 13 | 80% | 0.5% | 8 |
4 | VIRAL ONCOL PROGRAM | 11 | 33% | 1.6% | 28 |
5 | ABRAMSON COMPREHENS CANC | 11 | 30% | 1.8% | 32 |
6 | TUMOR VIROL GRP | 11 | 67% | 0.6% | 10 |
7 | MOL VIROL S | 10 | 50% | 0.8% | 15 |
8 | VIRAL ONCOGENESIS | 8 | 100% | 0.3% | 5 |
9 | VIRAL ONCOL GRP | 7 | 46% | 0.6% | 11 |
10 | ABT MOL EXPT CHIRURG | 6 | 100% | 0.2% | 4 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000270428 | KAPOSIS SARCOMA//HUMAN HERPESVIRUS 8//KAPOSI SARCOMA |
2 | 0.0000246944 | MHV 68//MURINE GAMMAHERPESVIRUS//MURINE GAMMAHERPESVIRUS 68 |
3 | 0.0000192366 | HERPESVIRUS SAIMIRI//KLIN MOL VIROL//STPC |
4 | 0.0000136932 | O I//VIRAL MICRORNAS//VIRAL MIRNA |
5 | 0.0000125618 | PLASMABLASTIC LYMPHOMA//PLASMABLASTIC//HUMAN IMMUNODEFICIENCY VIRUS NEGATIVE |
6 | 0.0000113596 | CASTLEMANS DISEASE//CASTLEMAN DISEASE//ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA |
7 | 0.0000073132 | BZLF1//BRLF1//VIRAL MOL TUMOR DIAGNOST UNIT |
8 | 0.0000072572 | CD83//SOLUBLE CD83//MARCH I |
9 | 0.0000058682 | LMP1//LATENT MEMBRANE PROTEIN 1//EBV |
10 | 0.0000053038 | AIDS RELATED LYMPHOMA//NON AIDS DEFINING CANCER//NON AIDS DEFINING CANCERS |